Diagnostic Value of FibroTouch and Non-invasive Fibrosis Indexes in Hepatic Fibrosis with Different Aetiologies.
APRI
Cirrhosis
FIB-4
FibroTouch
GPRI
Liver fibrosis
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
24
10
2019
accepted:
09
05
2021
pubmed:
2
6
2021
medline:
9
6
2022
entrez:
1
6
2021
Statut:
ppublish
Résumé
Liver biopsy is the gold standard for staging liver fibrosis, but it has numerous drawbacks, mainly associated with bleeding and bile fistula risks. A number of non-invasive techniques have been investigated, but they all have their own disadvantages. To avoid the risks mentioned above and to improve the diagnostic value, we still need to search for a more accurate non-invasive method to evaluate the degree of liver fibrosis. This study aimed to evaluate the diagnostic performance of FibroTouch versus other non-invasive fibrosis indexes in hepatic fibrosis of different aetiologies. This study retrospectively enrolled 227 patients with chronic hepatic liver disease admitted to the first hospital of Lanzhou University from 2017 to 2020. Liver biopsy was performed in all of the patients, and their biochemical indicators were all tested. Non-invasive indexes including the fibrosis index based on four factors (FIB-4), the aminotransferase-to-platelet ratio index (APRI), and the gamma-glutamyl transpeptidase-to-platelet ratio index (GPRI) were all calculated. Transient elastography was performed using FibroTouch. The correlation between FibroTouch and the pathology of liver fibrosis was significantly higher than that between the non-invasive fibrosis indexes and the biopsy results (r = 0.771, p < 0.05). The area under the receiver operating curve (AUC) of FibroTouch was significantly higher than that of FIB-4, APRI, and GPRI for the diagnosis of significant fibrosis (≥ S2 fibrosis stage), advanced fibrosis (≥ S3 fibrosis stage), and cirrhosis (= S4 fibrosis stage) (p < 0.05). The patients were grouped according to different aetiologies. The diagnostic value of FibroTouch had much higher credibility in different fibrosis stages for different causes compared with other non-invasive indexes. The AUC of FibroTouch showed both higher specificity and higher sensitivity than FIB-4, APRI, and GPRI for different liver fibrosis stages with different aetiologies. FibroTouch demonstrates the highest diagnostic value for liver fibrosis and cirrhosis among non-invasive methods, showing better results than FIB-4, APRI, and GPRI, and surpassed only by liver biopsy. FibroTouch is reliable in assessing liver fibrosis with different aetiologies.
Sections du résumé
BACKGROUND
Liver biopsy is the gold standard for staging liver fibrosis, but it has numerous drawbacks, mainly associated with bleeding and bile fistula risks. A number of non-invasive techniques have been investigated, but they all have their own disadvantages. To avoid the risks mentioned above and to improve the diagnostic value, we still need to search for a more accurate non-invasive method to evaluate the degree of liver fibrosis.
AIM
This study aimed to evaluate the diagnostic performance of FibroTouch versus other non-invasive fibrosis indexes in hepatic fibrosis of different aetiologies.
METHODS
This study retrospectively enrolled 227 patients with chronic hepatic liver disease admitted to the first hospital of Lanzhou University from 2017 to 2020. Liver biopsy was performed in all of the patients, and their biochemical indicators were all tested. Non-invasive indexes including the fibrosis index based on four factors (FIB-4), the aminotransferase-to-platelet ratio index (APRI), and the gamma-glutamyl transpeptidase-to-platelet ratio index (GPRI) were all calculated. Transient elastography was performed using FibroTouch.
RESULTS
The correlation between FibroTouch and the pathology of liver fibrosis was significantly higher than that between the non-invasive fibrosis indexes and the biopsy results (r = 0.771, p < 0.05). The area under the receiver operating curve (AUC) of FibroTouch was significantly higher than that of FIB-4, APRI, and GPRI for the diagnosis of significant fibrosis (≥ S2 fibrosis stage), advanced fibrosis (≥ S3 fibrosis stage), and cirrhosis (= S4 fibrosis stage) (p < 0.05). The patients were grouped according to different aetiologies. The diagnostic value of FibroTouch had much higher credibility in different fibrosis stages for different causes compared with other non-invasive indexes. The AUC of FibroTouch showed both higher specificity and higher sensitivity than FIB-4, APRI, and GPRI for different liver fibrosis stages with different aetiologies.
CONCLUSIONS
FibroTouch demonstrates the highest diagnostic value for liver fibrosis and cirrhosis among non-invasive methods, showing better results than FIB-4, APRI, and GPRI, and surpassed only by liver biopsy. FibroTouch is reliable in assessing liver fibrosis with different aetiologies.
Identifiants
pubmed: 34059990
doi: 10.1007/s10620-021-07049-4
pii: 10.1007/s10620-021-07049-4
doi:
Substances chimiques
Biomarkers
0
Aspartate Aminotransferases
EC 2.6.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2627-2636Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014;20:16820–16830.
doi: 10.3748/wjg.v20.i45.16820
Pencheva B, Mihajlov R, Ruseva A et al. Reference values of certain serum indicators of liver fibrosis. Clin Lab 2017;63:1793–1800.
pubmed: 29226638
Fricker J. European association for the study of the liver: international liver congress 2017 meeting. Lancet Oncol 2017;18:713.
doi: 10.1016/S1470-2045(17)30317-0
European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392–420.
doi: 10.1016/j.jhep.2013.11.003
Shiha G, Sarin SK, Ibrahim AE et al. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int 2009;3:323–333.
doi: 10.1007/s12072-008-9114-x
Gwon D 2nd, Ko GY, Yoon HK et al. Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: incidence, characteristics, and risk factors and clinical efficacy of TACE. Radiology. 2010;254:617–626.
doi: 10.1148/radiol.09090738
Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012;142:1293-1302.e4.
doi: 10.1053/j.gastro.2012.02.017
Yang XZ, Gen AW, Xian JC, Xiao L. Diagnostic value of various noninvasive indexes in the diagnosis of chronic hepatic fibrosis. Eur Rev Med Pharmacol Sci 2018;22:479–485.
pubmed: 29424906
Motola DL, Caravan P, Chung RT, Fuchs BC. Noninvasive biomarkers of liver fibrosis: clinical applications and future directions. Curr Pathobiol Rep 2014;2:245–256.
doi: 10.1007/s40139-014-0061-z
Onur MR, Poyraz AK, Bozdag PG, Onder S, Aygun C. Diffusion weighted MRI in chronic viral hepatitis: correlation between ADC values and histopathological scores. Insights Imaging 2013;4:339–345.
doi: 10.1007/s13244-013-0252-x
Li J, Venkatesh SK, Yin M. Advances in Magnetic Resonance Elastography of Liver. Magn Reson Imaging Clin N Am 2020;28:331–340.
doi: 10.1016/j.mric.2020.03.001
Chon YE, Choi EH, Song KJ et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS ONE 2012;7:e44930.
doi: 10.1371/journal.pone.0044930
Wong GL. Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol. 2014;20:228–236.
doi: 10.3350/cmh.2014.20.3.228
Zeng J, Sun WL, Chen GY et al. Efficiency of FibroScan and FibroTouch in liver stiffness measurement and fat quantification: a comparative analysis]. Zhonghua Gan Zang Bing Za Zhi. 2016;24:652–658.
pubmed: 27788720
Xu Y, Liu Y, Cao Z et al. Comparison of FibroTouch and FibroScan for staging fibrosis in chronic liver disease: Single-center prospective study. Dig Liver Dis. 2019;51:1323–1329.
doi: 10.1016/j.dld.2019.02.009
Ou X, Wang X, Wu X et al. Comparison of FibroTouch and FibroScan for the assessment of fibrosis in chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi. 2015;23:103–106.
pubmed: 25880975
Yuan L, Shao J, Hao M et al. Correlation between liver hardness testing results obtained by FibroTouch and FibroScan and liver pathological stage]. Zhonghua Gan Zang Bing Za Zhi 2014;22:425–429.
pubmed: 25203705
Tian A, Pu K, Li B et al. Weighted gene coexpression network analysis reveals hub genes involved in cholangiocarcinoma progression and prognosis. Hepatol Res 2019;49:1195–1206.
doi: 10.1111/hepr.13386
Nan Y, Niu X, Wang R et al. microRNA-1273g-3p is a useful non-invasive test for the prediction of liver fibrosis in patients with chronic hepatitis C. Exp Ther Med 2019;17:1817–1824.
pubmed: 30783454
Duan WJ, Wang XZ, Ma AL et al. Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis B. J Dig Dis 2020;21:519–525.
doi: 10.1111/1751-2980.12924
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69:406-460.
Zalesak M, Francis K, Gedeon A et al. Current and future disease progression of the chronic HCV population in the United States. PLoS ONE 2013;8:e63959.
doi: 10.1371/journal.pone.0063959
Tapper EB, Challies T, Nasser I, Afdhal NH, Lai M. The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2016;111:677–684.
doi: 10.1038/ajg.2016.49
Karlas T, Dietrich A, Peter V et al. Evaluation of Transient Elastography, Acoustic Radiation Force Impulse Imaging (ARFI), and Enhanced Liver Function (ELF) Score for Detection of Fibrosis in Morbidly Obese Patients. PLoS ONE 2015;10:e0141649.
doi: 10.1371/journal.pone.0141649
Wang YQ, Cao WJ, Gao YF, Ye J, Zou GZ. Serum interleukin-34 level can be an indicator of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol. 2018;24:1312–1320.
doi: 10.3748/wjg.v24.i12.1312
Deng H, Wang CL, Lai J, Yu SL, Xie DY, Gao ZL. Noninvasive diagnosis of hepatic steatosis using fat attenuation parameter measured by FibroTouch and a new algorithm in CHB Patients. Hepat Mon 2016;16:e40263.
doi: 10.5812/hepatmon.40263
Wang R, Ren W, Zhao S et al. Clinical study on FibroTouch and multi-parameter model for diagnosis of hepatic fibrosis in patients with chronic liver disease]. Zhonghua Gan Zang Bing Za Zhi 2015;23:265–269.
pubmed: 26133817
Zeremski M, Talal AH. Noninvasive markers of hepatic fibrosis: are they ready for prime time in the management of HIV/HCV co-infected patients. J Hepatol 2005;43:2–5.
doi: 10.1016/j.jhep.2005.05.007
Weng H, Mertens PR, Gressner AM, Dooley S. IFN-gamma abrogates profibrogenic TGF-beta signaling in liver by targeting expression of inhibitory and receptor Smads. J Hepatol 2007;46:295–303.
doi: 10.1016/j.jhep.2006.09.014
Wang RQ, Zhang QS, Zhao SX et al. Gamma-glutamyl transpeptidase to platelet ratio index is a good noninvasive biomarker for predicting liver fibrosis in Chinese chronic hepatitis B patients. J Int Med Res 2016;44:1302–1313.
doi: 10.1177/0300060516664638
[The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. Zhonghua Gan Zang Bing Za Zhi 2019;27:938–961.
[Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update]. Zhonghua Gan Zang Bing Za Zhi 2019;27:182–191.
Wu S, Yang Z, Zhou J et al. Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis. Hepatol Int 2019;13:91–101.
doi: 10.1007/s12072-018-9907-5
Das K, Sarkar R, Ahmed SM et al. “Normal” liver stiffness measure (LSM) values are higher in both lean and obese individuals: a population-based study from a developing country. Hepatology 2012;55:584–593.
doi: 10.1002/hep.24694
Coco B, Oliveri F, Maina AM et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007;14:360–369.
doi: 10.1111/j.1365-2893.2006.00811.x
Degos F, Perez P, Roche B et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010;53:1013–1021.
doi: 10.1016/j.jhep.2010.05.035
Shiha G, Ibrahim A, Helmy A et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int 2017;11:1–30.
doi: 10.1007/s12072-016-9760-3